Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GLAXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLAXF SEC filings page on Stock Titan provides access to US regulatory documents filed by GSK plc, a global biopharma company. As a foreign private issuer, GSK submits an annual Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934. These filings, sourced from EDGAR, cover product approvals, clinical trial outcomes, regulatory milestones and detailed transaction notifications for persons discharging managerial responsibilities (PDMRs).
For investors analysing GLAXF, GSK’s 6-K reports are a primary source of information on its vaccines, respiratory and immunology portfolio, and infectious disease pipeline. Recent filings describe European Commission approval of a prefilled syringe presentation for Shingrix, GSK’s recombinant zoster vaccine, and regulatory approvals in Japan for Exdensur (depemokimab) in severe asthma and chronic rhinosinusitis with nasal polyps. Other 6-Ks outline phase III B-Well 1 and B-Well 2 trial results for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, including definitions of functional cure and key efficacy findings.
GSK’s filings also contain structured PDMR transaction notifications. These tables specify the financial instrument (ordinary shares of 31¼ pence each), ISIN (GB00BN7SWP63), nature of the transaction (such as acquisition of shares via dividend reinvestment or share reward plans), price, volume, date and trading venue (London Stock Exchange). This information allows users to track insider-related share dealings through Form 6-K disclosures.
On Stock Titan, each new GSK 6-K or 20-F is captured and can be paired with AI-powered summaries that explain the main points in plain language. Users can quickly identify filings related to vaccines, respiratory biologics, hepatology candidates or PDMR share activity, and then drill into the original documents for full legal and scientific detail.
GSK plc reports that on 05 December 2025 it repurchased 248,000 of its ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,798.00p and 1,833.00p per share, with a volume-weighted average price of 1,818.74p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back a total of 12,245,733 ordinary shares. Following this latest purchase, the company holds 237,710,577 shares in treasury and has 4,077,728,560 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares now represent 5.83% of its voting rights, a figure shareholders can use when assessing notification thresholds under UK disclosure rules.
GSK plc reports that it repurchased 233,000 of its ordinary shares of 31¼ pence each on 4 December 2025 under its existing share buyback programme, using BNP Paribas SA as broker. The shares were bought at prices between 1,819.00p and 1,852.50p per share, with a volume-weighted average price of 1,832.36p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought 11,997,733 ordinary shares under this programme. After this latest purchase, GSK holds 237,462,577 shares in treasury and has 4,077,971,107 ordinary shares in issue, which is also the total number of voting rights. The company states that, following this transaction, treasury shares represent 5.82% of the voting rights.
GSK plc reports that on 03 December 2025 it repurchased 218,000 ordinary shares of 31¼ pence each through BNP Paribas SA under its existing share buyback programme. The shares were bought at prices between 1,830.00p and 1,848.00p, with a volume-weighted average price of 1,839.30p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 11,764,733 ordinary shares under this programme. After this latest transaction, GSK holds 237,229,577 ordinary shares in treasury and has 4,078,204,107 ordinary shares in issue, giving a total of 4,078,204,107 voting rights. The percentage of voting rights attributable to treasury shares is stated as 5.82 per cent.
GSK plc reports that on 02 December 2025 it repurchased 200,000 of its ordinary shares of 31¼ pence each through BNP Paribas SA as part of its existing share buyback programme. The shares were bought at prices between 1,783.00p and 1,827.00p, with a volume-weighted average price of 1,815.48p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased a total of 11,546,733 ordinary shares under this programme. After the latest transaction, the company holds 237,011,577 shares in treasury and has 4,078,422,107 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares represent 5.81 per cent of the voting rights, a figure relevant for shareholders’ disclosure calculations under UK rules.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 203,000 ordinary shares on 01 December 2025 as part of its existing share buyback programme. The shares, with a nominal value of 31¼ pence each, were bought at prices between 1,786.00p and 1,810.00p, with a volume-weighted average price of 1,800.44p.
After this transaction, GSK holds 236,811,577 ordinary shares in treasury and has 4,078,622,107 ordinary shares in issue excluding treasury shares. The total number of voting rights in GSK is 4,078,622,107, and the company states that treasury shares represent 5.81% of the voting rights, which shareholders can use as a reference for regulatory disclosure thresholds.
GSK plc filed a Form 6-K reporting option grants to three senior executives under the Company’s Share Save Plan 2022. James Ford (SVP and Group General Counsel, Legal and Compliance), David Redfern (President, Corporate Development), and Victoria Whyte (SVP & Company Secretary) each received options over 643 Ordinary Shares of 31¼ pence at an option price of £14.19 per share.
The grants were made on 2025-11-28 and relate to GSK’s Ordinary Shares with ISIN GB00BN7SWP63, with the transactions conducted on the London Stock Exchange (XLON). These awards form part of GSK’s regular share-based compensation for senior management and do not change the company’s stated business strategy as a global biopharma company.
GSK plc reports its share capital and voting rights position as at 30 November 2025. The company had 4,315,433,684 issued Ordinary Shares of 31 ¼ pence each, of which 236,608,577 Ordinary Shares were held in treasury. After excluding the treasury shares, the total number of voting rights in GSK is 4,078,825,107. Shareholders can use this voting-rights figure to determine whether they need to notify GSK and the UK regulator of any changes in their shareholdings under the applicable transparency rules.
GSK plc reports that, on 28 November 2025, it repurchased 250,000 ordinary shares of 31¼ pence each through BNP Paribas SA as part of its existing share buyback programme. The shares were bought at prices between 1,786.00p and 1,809.50p per share, with a volume‑weighted average price of 1,799.00p, and will be held as treasury shares.
Since 30 September 2025, GSK has purchased 11,143,733 ordinary shares under this programme. After these latest purchases, GSK holds 236,608,577 shares in treasury and has 4,078,825,107 ordinary shares in issue, giving a total of 4,078,825,107 voting rights. GSK states that treasury shares represent 5.80% of its voting rights, a figure shareholders can use when determining notification obligations under UK disclosure rules.
GSK plc reports that, acting through BNP Paribas SA, it repurchased 245,000 ordinary shares of 31¼ pence each on 27 November 2025 as part of its existing share buyback programme. The shares were bought at prices between 1,795.50p and 1,812.00p per share, with a volume‑weighted average price of 1,804.14p, and will be held as treasury shares.
Since 30 September 2025, GSK has bought back 10,893,733 ordinary shares. After this latest transaction, it holds 236,358,577 shares in treasury and has 4,079,073,350 ordinary shares in issue, which is also the total number of voting rights. GSK states that treasury shares now represent 5.79% of voting rights, a figure investors can use for ownership and disclosure calculations.
GSK plc reports that it bought back 170,733 of its ordinary shares on 26 November 2025 through BNP Paribas SA, at prices between 1,794.50p and 1,819.50p per share, with a volume-weighted average price of 1,807.55p. These shares will be held as treasury shares as part of the company’s existing buyback programme, which has repurchased 10,648,733 shares since 30 September 2025.
After this transaction, GSK holds 236,113,577 shares in treasury and has 4,079,318,350 ordinary shares in issue, which is also the total number of voting rights in the company. GSK confirms that treasury shares now represent 5.79% of the voting rights, a figure shareholders can use when assessing disclosure thresholds under UK transparency rules.
FAQ
What is the current stock price of GSK PLC (GLAXF)?
